Stacy P Ardoin, Laura Eve Schanberg, Christy I Sandborg, Huiman X Barnhart, Greg W Evans, Eric Yow, Kelly L Mieszkalski, Norman T Ilowite, Anne Eberhard, Lisa F Imundo, Yuki Kimura, Deborah Levy, Emily von Scheven, Earl Silverman, Suzanne L Bowyer, L Punaro, Nora G Singer, David D Sherry, Deborah K McCurdy, Marissa Klein-Gitelman, Carol Wallace, Richard M Silver, Linda Wagner-Weiner, Gloria C Higgins, Hermine I Brunner, Lawrence Jung, Jennifer B Soep, Ann M Reed, Susan D Thompson
OBJECTIVE: Participants in the Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants showed a trend of slower CIMT progression. Post-hoc analyses were performed to assess subgroup benefit from atorvastatin therapy. METHODS: Subgroups were prespecified and defined by age (> or ≤15...
March 2014: Annals of the Rheumatic Diseases